Home » Conference Highlights » AHA 2021 Heart Failure In-depth
AHA 2021 Heart Failure In-Depth
Researchers sought to determine whether dapagliflozin could help reverse left ventricular remodeling in patients with type 2 diabetes.
Researchers analyzed the effects of using tolvaptan as add-on therapy for patients hospitalized with acute heart failure.
Through a subanalysis of the REALITY-AHF study, researchers were able to assess the negative effects of an early drop in systolic blood pressure in patients with acute heart failure.
ARNI vs ACE inhibitors or ARB and outcomes in patients with HFrEF.
Study investigators analyzed the effects of MRA cessation on risk-benefit balance of patients with heart failure and hyperkalemia.
Researchers examined the outcomes of GLP-1 receptor agonist therapy in patients with heart failure.
Open
Next post in AHA 2021 Heart Failure In-depth
Close
Close more info about Dapagliflozin Has No Significant Effect on Cardiac Remodeling in T2D
Loading...
Close more info about Dapagliflozin Has No Significant Effect on Cardiac Remodeling in T2D
Loading...